Clinical trials: Minimal Change Disease
Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion
A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease
This is a parallel, Phase 2a, double-blind, 6-arm study for the treatment of primary focal segmental glomerulosclerosis (FSGS) or minimal change disease (MCD).
- Trial name
- RESULT (NCT06500702)
- Testing
- frexalimab, brivekimig, rilzabrutinib
- Where
- 79 sites in United States, Argentina and 20 more
- Volunteers
- 84 people
- Sponsor
- Sanofi
Nephrotic Syndrome
INSIGHT (Insight Into Nephrotic Syndrome)
INSIGHT is a longitudinal study of childhood nephrotic syndrome to determine genetic, serologic and environmental factors contributing to nephrotic syndrome and disease progression.
- Trial name
- INSIGHT (NCT01605266)
- Where
- 4 sites in Canada
- Volunteers
- 1,000 people
- Sponsor
- The Hospital for Sick Children
Focal Segmental Glomerulosclerosis
Allogenic AD-MSC Transplantation in Idiopathic Nephrotic Syndrome (Focal Segmental Glomerulosclerosis)
Idiopathic Focal Segmental Glumero Sclerosis (FSGS) is not very common but important manifestation of kidney disease. FSGS has poor prognosis among the patterns of Idiopathic Nephrotic Syndrome (INS).
- Trial name
- NCT02382874
- Testing
- Intravenous injection
- Where
- Iran
- Volunteers
- 5 people
- Sponsor
- Royan Institute
Dental Caries, Dental Caries in Children
Atraumatic Versus Silver-Modified Atraumatic Restorative Treatment in Primary Molars
The goal of this clinical trial is to evaluate and compare the short-term effectiveness of two minimally invasive treatments-Atraumatic Restorative Treatment (ART) and Silver-Modified Atraumatic Restorative Treatment (SMART)-in…
- Trial name
- NCT07023939
- Testing
- ART: Atraumatic restorative treatment, SMART: Silver-Modified Atraumatic Restorative Treatment
- Where
- Lebanon
- Volunteers
- 34 people
- Sponsor
- Beirut Arab University
CD19 Positive, CD22 Positive
Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma
This phase I/II trial studies the side effects and best dose of modified immune cells called CD19-CD22 chimeric antigen receptor (CAR) T cells in treating patients with CD19 positive(+), CD22+ B-acute lymphoblastic leukemia…
- Conditions
- CD19 Positive, CD22 Positive, Minimal Residual Disease, Progressive Disease
- Trial name
- NCT04029038
- Testing
- Autologous CD19/CD22 Chimeric Antigen Receptor T-cells, Cyclophosphamide, Fludarabine
- Where
- United States
- Sponsor
- M.D. Anderson Cancer Center
Healthy Volunteers
MRCP: A Reliable, Non Invasive Method for Staging Chronic Pancreatitis in Pediatrics
The goal of this research study is to learn more about the pancreas. The investigators want to use Magnetic Resonance Cholangiopancreatography (MRCP) to learn more about the size of a normal pancreas.
- Trial name
- NCT02869893
- Testing
- Secretin
- Where
- United States
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Nephrotic Syndrome in Children, Minimal Change Disease
taVNS for FRNS in Children
Children with frequently relapsing nephrotic syndrome (FRNS) are exposed to prolonged courses of steroids and other immunosuppressant medications.
- Conditions
- Nephrotic Syndrome in Children, Minimal Change Disease, Focal Segmental Glomerulosclerosis
- Trial name
- kidNEY-VNS (NCT05588063)
- Testing
- Transcutaneous auricular vagus nerve stimulation
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Northwell Health
Kidney Disease, Glomerular Disease
Kidney Disease Biomarkers
Kidney Disease Biomarkers Summary: This study will identify biomarkers (proteins and other molecules in the blood or urine) that may help scientists predict what kidney disease a patient has and whether a given patient would…
- Conditions
- Kidney Disease, Glomerular Disease, Idiopathic Nephrotic Syndrome, Focal Segmental Glomerulosclerosis
- Trial name
- NCT00255398
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Nephrotic Syndrome in Children, Steroid-Dependent Nephrotic Syndrome
Reduce Immunosuppression With Atmp in NS ChildrEn
A phase II open-label, single arm study aimed to ascertain whether infusions of cord-blood mesenchymal stromal cells (CB-MSCs) allow to reduce or suspend the chronic immunosuppressive therapy (IS) in steroid-dependent nephrotic…
- Conditions
- Nephrotic Syndrome in Children, Steroid-Dependent Nephrotic Syndrome, Idiopathic Nephrotic Syndrome
- Trial name
- RACE (NCT04034316)
- Testing
- Cord-blood mesenchymal stromal cells
- Where
- Italy
- Volunteers
- 20 people
- Sponsor
- Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
Focal Segmental Glomerulosclerosis, Steroid Resistant Nephrotic Syndrome
Oral Galactose in Children With Steroid Resistant Nephrotic Syndrome
Focal Segmental Glomerulosclerosis (FSGS) is a devastating kidney disease which is difficult to treat and carries a poor prognosis, with 50% of affected children progressing to end stage renal disease (ESRD).
- Trial name
- NCT01113385
- Testing
- D-Galactose
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Children's National Research Institute
First Manifestation of Steroid Sensitive Nephrotic Syndrome
Efficiency of Levamisole for Maintaining Remission After the First Flare of Steroid Sensitive Nephrotic Syndrome in Children
Idiopathic Nephrotic Syndrome is sensitive to steroid in 90% of children. However, most patients relapse and become steroid-dependant, with a long lasting relapsing course.
- Trial name
- NEPHROVIR3 (NCT02818738)
- Testing
- Levamisole Hydrochloride
- Where
- France
- Volunteers
- 86 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
FSGS, MCD
Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease
Adalimumab, a treatment which blocks tumor necrosis factor (TNF), was tested to see if it changed levels of urine biomarker levels, tissue inhibitor of metalloprotease-1 (TIMP1), and monocyte chemoattractant protein-1 (MCP1).
- Conditions
- FSGS, MCD, Focal Segmental Glomerulosclerosis, Minimal Change Disease
- Trial name
- NCT04009668
- Testing
- adalimumab
- Where
- 4 sites in United States
- Volunteers
- 7 people
- Sponsor
- University of Michigan
Urinary Incontinence
Clinically Important or Just Statistically Significant? MCID for DVISS and PIN-Q in Children With UI
The goal of this study was to determine the Minimal Clinically Important Difference (MCID) for the Dysfunctional Voiding and Incontinence Symptom Score (DVISS) and the Pediatric Incontinence Questionnaire (PIN-Q) in children with…
- Trial name
- NCT07242898
- Testing
- Standard Urotherapy (SU)
- Volunteers
- 100 people
- Sponsor
- Artvin Coruh University
Idiopathic Nephrotic Syndrome
Factors of Steroid Dependency in Idiopathic Nephrotic Syndrome
The primary purpose of the study is to identify the factors of steroid dependency in childhood idiopathic nephrotic syndrome. The steroid dependency is defined by a relapse of nephrotic syndrome within the 3 weeks that follow the…
- Trial name
- NEPHROVIR-2 (NCT01609426)
- Testing
- DNA chip dedicated to the pharmacogenetic of steroids
- Where
- France
- Volunteers
- 351 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hematologic Malignancy
Safety/PK Study of Gene Modified Donor T Cell Infusion in Children With Recurrent Hem Malignancies After Allo Transplant
Phase I, open-label, non-randomized study of safety, pharmacokinetics and efficacy of donor BPX-501 T cell infusion in children with recurrent or minimal residual disease (MRD) hematologic malignancies post-allogeneic transplant.
- Trial name
- NCT03459170
- Testing
- BPX-501 T cells, rimiducid
- Where
- 3 sites in Italy
- Volunteers
- 15 people
- Sponsor
- Bellicum Pharmaceuticals
Nephrotic Syndrome
Diagnostic and Prognostic Value of Miss-1 Study in Children and Adult With Nephrotic Syndrome MISSNEPHROTIQUE
The nephrotic syndrome is a rare disease defined by a proteinuria >3g/24h and a hypoalbuminemia < 30g/L. Genetic and immune are the main causes.
- Trial name
- MISS-N (NCT03592030)
- Where
- France
- Volunteers
- 150 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Glomerular Disease, Minimal Change Disease
KOrea Renal Biobank NEtwoRk System TOward NExt-generation Analysis
Glomerulonephritis (GN) generates an enormous individual and social economic burden. However, the therapeutic options are largely based on clinical and pathological parameters and the individual response to therapy or prognosis…
- Conditions
- Glomerular Disease, Minimal Change Disease, IgA Nephropathy, Membranous Nephropathy
- Trial name
- KORNERSTONE (NCT03929887)
- Testing
- Kidney Biopsy
- Where
- 6 sites in South Korea
- Volunteers
- 3,000 people
- Sponsor
- Seoul National University Hospital
Focal Segmental Glomerulosclerosis, Minimal Change Disease
Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis and Minimal Change Disease
The morbidity of recurrence of focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD) after transplant is well-recognized and include contemporary reduction in quality of life, edema, early graft loss and…
- Conditions
- Focal Segmental Glomerulosclerosis, Minimal Change Disease, FSGS, MCD
- Trial name
- RESOLVE (NCT05650619)
- Testing
- Biospecimen collection, Data collection
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- University of Michigan
Idiopathic Nephrotic Syndrome
Short-term gluCOCOrticoid in Adult STEROID-sensitive Nephrotic Syndrome: The COCO-ASTEROID Study
This study will compare a short-term course (12 week) glucocorticoid regimen with the Conventional 24-week regimen as originally proposed by KDIGO.
- Trial name
- NCT07151456
- Testing
- Conventional 24-week glucocorticoid regimen, short-term course (12 week) glucocorticoid regimen
- Where
- China
- Volunteers
- 224 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
Focal Segmental Glomerulosclerosis, Minimal Change Disease
Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases
To evaluate the safety, efficacy and tolerability of sparsentan oral suspension and tablets, and assess changes in proteinuria after once-daily dosing over 108 weeks.
- Conditions
- Focal Segmental Glomerulosclerosis, Minimal Change Disease, Immunoglobulin A Nephropathy, IgA Vasculitis
- Trial name
- EPPIK (NCT05003986)
- Testing
- Sparsentan
- Where
- 47 sites in United States, Germany and 6 more
- Volunteers
- 67 people
- Sponsor
- Travere Therapeutics, Inc.